These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32904788)

  • 1. Vaccination Prevented Short-Term Memory Loss, but Deteriorated Long-Term Spatial Memory in Alzheimer's Disease Mice, Independent of Amyloid-β Pathology.
    Oberman K; Gouweleeuw L; Hoogerhout P; Eisel ULM; van Riet E; Schoemaker RG
    J Alzheimers Dis Rep; 2020 Jul; 4(1):261-280. PubMed ID: 32904788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Time Course of Recognition Memory Impairment and Glial Pathology in the hAPP-J20 Mouse Model of Alzheimer's Disease.
    Ameen-Ali KE; Simpson JE; Wharton SB; Heath PR; Sharp PS; Brezzo G; Berwick J
    J Alzheimers Dis; 2019; 68(2):609-624. PubMed ID: 30814360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice.
    Mably AJ; Liu W; Mc Donald JM; Dodart JC; Bard F; Lemere CA; O'Nuallain B; Walsh DM
    Neurobiol Dis; 2015 Oct; 82():372-384. PubMed ID: 26215784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer's disease.
    Kim WS; Li H; Ruberu K; Chan S; Elliott DA; Low JK; Cheng D; Karl T; Garner B
    J Neurosci; 2013 Mar; 33(10):4387-94. PubMed ID: 23467355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
    Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
    J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid β-Associated Alzheimer's Disease in Mice.
    Ricke KM; Cruz SA; Qin Z; Farrokhi K; Sharmin F; Zhang L; Zasloff MA; Stewart AFR; Chen HH
    J Neurosci; 2020 Feb; 40(7):1581-1593. PubMed ID: 31915254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
    Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p110δ PI3-Kinase Inhibition Perturbs APP and TNFα Trafficking, Reduces Plaque Burden, Dampens Neuroinflammation, and Prevents Cognitive Decline in an Alzheimer's Disease Mouse Model.
    Martínez-Mármol R; Mohannak N; Qian L; Wang T; Gormal RS; Ruitenberg MJ; Vanhaesebroeck B; Coulson EJ; Meunier FA
    J Neurosci; 2019 Oct; 39(40):7976-7991. PubMed ID: 31363064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology.
    Gnoth K; Piechotta A; Kleinschmidt M; Konrath S; Schenk M; Taudte N; Ramsbeck D; Rieckmann V; Geissler S; Eichentopf R; Barendrecht S; Hartlage-Rübsamen M; Demuth HU; Roßner S; Cynis H; Rahfeld JU; Schilling S
    Alzheimers Res Ther; 2020 Nov; 12(1):149. PubMed ID: 33189132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
    Petrushina I; Ghochikyan A; Mktrichyan M; Mamikonyan G; Movsesyan N; Davtyan H; Patel A; Head E; Cribbs DH; Agadjanyan MG
    J Neurosci; 2007 Nov; 27(46):12721-31. PubMed ID: 18003852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory.
    Arendash GW; Gordon MN; Diamond DM; Austin LA; Hatcher JM; Jantzen P; DiCarlo G; Wilcock D; Morgan D
    DNA Cell Biol; 2001 Nov; 20(11):737-44. PubMed ID: 11788052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
    Zueva IV; Semenov VE; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS
    Int J Risk Saf Med; 2015; 27 Suppl 1():S69-71. PubMed ID: 26639718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist.
    Fitz NF; Castranio EL; Carter AY; Kodali R; Lefterov I; Koldamova R
    J Alzheimers Dis; 2014; 41(2):535-49. PubMed ID: 24643138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model.
    Fabbro S; Schaller K; Seeds NW
    J Neurochem; 2011 Sep; 118(5):928-38. PubMed ID: 21689108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
    Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
    J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.
    Koppel J; Vingtdeux V; Marambaud P; d'Abramo C; Jimenez H; Stauber M; Friedman R; Davies P
    Mol Med; 2014 Mar; 20(1):29-36. PubMed ID: 24722782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.
    Maier M; Seabrook TJ; Lazo ND; Jiang L; Das P; Janus C; Lemere CA
    J Neurosci; 2006 May; 26(18):4717-28. PubMed ID: 16672644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease.
    Brunner D; Flunkert S; Neddens J; Duller S; Scopes DIC; Treherne JM; Hutter-Paier B
    Neurosci Lett; 2017 Nov; 660():96-102. PubMed ID: 28917978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
    Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
    J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.